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Abstract
Background: Most clinical trials of antipsychotics in children are brief, failing to address their long-term safety,
particularly when taken concurrently with other psychotropics. This hypothesis-generating analysis evaluates
potential correlates of weight gain in children receiving extended risperidone treatment.
Methods: Medically healthy 7–17 year-old patients treated with risperidone for six months or more were enrolled.
Anthropometric measurements were conducted. Developmental and medication history was obtained from the
medical record. Information related to birth weight, dietary intake, physical activity, and parental weight was
collected. Mixed regression analyses explored the contribution of various demographic and clinical factors to age-
and sex-adjusted weight and body mass index (BMI) z scores over the treatment period.
Results: The sample consisted of 110 patients (89% males) with a mean age of 11.8 years (sd = 2.9) upon
enrollment. The majority had an externalizing disorder and received 0.03 mg/kg/day (sd = 0.02) of risperidone, for
2.5 years (sd = 1.7), to primarily target irritability and aggression (81%). Polypharmacy was common with 71%
receiving psychostimulants, 50% selective serotonin reuptake inhibitors (SSRIs), and 32% α2-agonists. Weight and
BMI z score were positively correlated with baseline weight at the start of risperidone, treatment duration, and the
weight-adjusted dose of risperidone but inversely associated with the weight-adjusted dose of psychostimulants
and the concurrent use of SSRIs and α2-agonists. The effect of risperidone dose appeared to attenuate as treatment
extended while that of psychostimulants became more significant. The rate of change in weight (or BMI) z score
prior to and within the first 12 weeks of risperidone treatment did not independently predict future changes
neither did birth weight, postnatal growth, dietary intake, physical activity, or parental weight.
Conclusions: This comprehensive analysis exploring correlates of long-term weight (or BMI) change in risperidone-
treated youths revealed that pharmacotherapy exerts significant but complex effects.
Trial Registration: Not applicable.
Keywords: Child, Adolescent, Weight gain, Obesity, Antipsychotics, Risperidone, Predictors
Background
The use of atypical antipsychotics (AAPs) in children
and adolescents has risen sharply over the last decade
[1,2]. Several AAPs have received FDA approval for
treatment of pediatric psychiatric conditions [3-6].
Moreover, AAPs in general, and risperidone in particu-
lar, significantly reduce irritability and aggression, which
contributes to expanding their use to the more com-
monly-occurring disruptive behavior disorders [7,8].
Thus, given that further rise in the prescribing of AAPs
to youths is anticipated, optimizing safety and tolerabil-
ity is imperative. This is especially true since most
pediatric psychiatric disorders targeted with AAPs are
chronic, necessitating extended treatment [9,10].
One particularly concerning AAP-related adverse
event is developmentally-inappropriate weight gain
[11,12]. Obesity is an increasingly prevalent cardiometa-
bolic risk factor leading to insulin resistance,
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dyslipidemia, and hypertension, among other sequelae
[13]. Childhood obesity, specifically, is worrisome as it is
strongly associated with adverse cardiometabolic condi-
tions in adulthood [14]. Thus, AAP-induced weight gain
in this vulnerable population has raised considerable
concerns among clinicians and the public alike [15,16].
In fact, substantial evidence has linked the use of most
AAPs to weight gain, with this outcome being particu-
larly prominent in youths [12,17]. Still, significant inter-
individual variability exists in the susceptibility to gain
weight during AAP treatment, both in adult and
pediatric samples [12,17]. Thus, identifying factors asso-
ciated with weight gain during AAP treatment can help
clinicians better estimate the risk/benefit ratio during
the decision-making process.
To that end, research investigating childhood predic-
tors of adult obesity can be informative. Specifically,
such characteristics as birth weight [18], postnatal
weight gain [19], physical activity [20], and dietary intake
[20] have all been implicated in obesity risk. However,
their contribution to the propensity to gain weight from
AAPs has not been fully explored. Moreover, while a few
studies have linked weight at the start of AAP treatment
[11,21,22], AAP dose [12], the rate of weight gain during
the first few weeks of AAP treatment [22,23], and poly-
pharmacy [24] to AAP-induced weight gain in relatively
short-term pediatric studies, these factors have not been
thoroughly researched during long-term AAP treatment.
Thus, the aim of this hypothesis-generating analysis
was to investigate whether the various demographic and
clinical factors reviewed above affect weight gain during
long-term risperidone treatment. Risperidone remains
the best-studied and most widely used AAP in youth
[1,5-7]. We hypothesized that low birth weight, rapid
postnatal growth, and higher doses of risperidone will
be associated with excessive weight gain. Conversely,
high physical activity, a healthy diet, and co-treatment




This study has been previously described [11,25]. Briefly,
7 to 17 year-old patients treated with risperidone for six
months or more were enrolled, irrespective of their pri-
mary psychiatric diagnosis or indication for risperidone.
Concurrent treatment with additional psychotropics at
enrollment, but not with other antipsychotics, was
allowed. Subjects with neurological or medical condi-
tions that could confound the metabolic assessments
were excluded as were pregnant females and those re-
ceiving hormonal contraception. The primary aim of
the study was to investigate the metabolic, hormonal,
and skeletal adverse events of risperidone during long-
term use.
Procedures
This study was approved by the local Institutional Re-
view Board. Written assent was obtained from children ≤
14 years old and consent from adolescents and parents
or guardians.
We recorded, from the medical record, the start and
stop dates of each psychotropic, changes in the dosage
and formulation, and the indication for risperidone. All
dosages of psychostimulants were expressed in methyl-
phenidate equivalents for amphetamines (x 2) [11]. We
defined an SSRI unit as being equivalent to a daily dose
of 10 mg of escitalopram, 20 mg of citalopram, fluoxet-
ine, or paroxetine, and 50 mg of sertraline or fluvox-
amine [25].
Upon enrollment, height was measured to the nearest
0.1 cm using a stadiometer (Holtain Ltd., UK) and
weight was recorded to the nearest 0.1 kg using a digital
scale (Scaletronix, Wheaton, IL), while wearing indoor
clothes without shoes. In addition, we extracted, from
the medical record, all height and weight measurements.
When both were available, body mass index (BMI, kg/
m2) was computed. However, since clinicians are more
likely to measure weight than height, the database con-
tained more than twice as many measurements for
weight as for height or BMI. Importantly, measurements
collected during clinic visits falling within a month of
the research visits were highly correlated with the re-
search measurements [mean interval = 16 days (sd = 9)
for height (n = 69) and 17 days (sd = 9) for weight
(n = 97)]. The intra-class correlations were all above 0.97
(95% confidence intervals [CI] ranging between 0.96 -
0.99) for unadjusted height and weight as well as for
their sex- and age-adjusted z scores.
A best-estimate diagnosis, following the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR)
[26], was generated based on a review of the psychiatric
record often supplemented by a brief clinical interview, a
standardized interview of the parent using the NIMH
Diagnostic Interview Schedule for Children (DISC-IV;
N= 95, 58%) [27], and the Child Behavior Checklist
(N= 120, 74%) [28].
At enrollment, the parent completed a questionnaire
regarding the pregnancy, the child’s birth weight, and
current parental height and weight. The intraclass cor-
relation coefficient between parental report and birth
record was 0.91 for birth weight (95% CI = 0.86-0.95,
n = 62) and 0.86 for duration of gestation (95% CI = 0.78-
0.92, n = 57). Thus, parental report was used when the
actual birth record could not be obtained. In addition,
three groups were defined based on a change of 0.67 z
score point in weight between birth and 2 years of life
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[19]. This magnitude of change has been recommended
to select children with significant postnatal growth and
corresponds to the width of each percentile band (e.g., 3,
10, 25, etc.) on standard growth charts [19].
The participants completed the 2004 Block Kids Food
Frequency Questionnaire, with assistance from the par-
ent when necessary [29]. This was reviewed by a re-
search dietician to confirm completeness and accuracy.
This questionnaire estimates the daily caloric intake
and diet composition during the week prior to
enrollment.
We also asked the subjects, with parental assistance
when necessary, to list the five physical activities they
participate in the most and to estimate the number of
days per week that they engage in each one. This
allowed computing the average number of days per week
that the child engages in at least one of these five activ-
ities prior to enrollment. Furthermore, they reported
the duration of their sleep and screen time (i.e., time
spent watching television or playing video games and
gameboy). Finally, using a five-point Likert scale, the
parent compared their child’s activity level to same-age
peers [11].
Data analysis
This hypothesis-generating analysis aimed to identify
which demographic and clinical variables were asso-
ciated with weight gain during extended treatment with
risperidone. However, in order to account for the natural
growth observed in children monitored over several
years, weight and BMI measurements were converted
into age- and sex-adjusted z scores using the 2000 Cen-
ter for Disease Control normative data [30]. A z score
refers to the number of standard deviations above or
below the mean, in a particular population. Similarly, a z
score was generated for birth weight, adjusting for gen-
der and gestational age [31].
In order to model weight (or BMI) z score change
after risperidone was started, a hierarchical linear mixed
model analysis was used to fit the trajectory of sex-age-
adjusted weight (or BMI) z score over time by estimating
a mean curve for weight (or BMI) z score over time for
the overall group from the individual curve of each
child. Thus, the model included both a fixed and ran-
dom effect for intercept and slope (i.e., time), to repre-
sent the mean curve and the random variation of each
child’s curve from the mean curve, respectively. The
selected covariates of baseline weight (or BMI) z score
(i.e., one obtained on or within a month before starting
risperidone), weight-adjusted (mg/kg) daily dose of ris-
peridone, age when risperidone was started, and weight-
adjusted (mg/kg) daily dose of psychostimulants were
included in this “primary” model since they have either
been shown to affect AAP-induced weight (or BMI) gain
or because there was a theoretical reason to believe so
[11]. Interactive effects between time and other variables
were tested and the significant ones were kept in the
model. Because we anticipated that weight gain will plat-
eau at some point after risperidone is started, the log
transform of time was used in the model. Since BMI
normally declines before it “rebounds” between 2.0 and
5.5 years of age, those measurements recorded before
age 5.5 were excluded from the BMI analyses [30]. Fi-
nally, since the participants (7%) could have received
antipsychotics other than risperidone prior to, but not
at, enrollment, observations obtained after initiation of
AAPs other than risperidone were excluded from the
analysis.
Additional variables were subsequently added to the
“primary” model to explore their independent contribu-
tion to risperidone-induced weight (or BMI) gain. When
several related variables were tested (e.g., diet or physical
activity), a backward model selection was applied to re-
move non-significant (α >5%) effects from the mixed re-
gression model.
We also aimed to evaluate the association between
change in weight prior to risperidone treatment with the
change afterwards. For instance, we sought to explore
whether children who might have lost weight before ris-
peridone was started, presumably due to psychostimu-
lants [32], exhibited accelerated weight gain with
risperidone. Thus, we initially regressed weight (or BMI)
z scores, obtained before starting risperidone, on time.
This analytical method was used because, in this obser-
vational study, weight (or BMI) measurements were col-
lected at the discretion of the clinicians, at varying time
points during the course of treatment. The slope esti-
mate of change in weight (or BMI) z score over time
was standardized by dividing it by its own standard devi-
ation in order to adjust for the variability in the number
of observations used to estimate the slope for each sub-
ject. The standardized slope from this linear regression
model was, subsequently, added to the “primary” linear
mixed model as an additional predictor. A similar ap-
proach was used to model weight change during the first
three months of risperidone treatment in order to ex-
plore whether it was associated with further weight gain.
All the statistical tests performed were two-tailed,
using SAS version 9.2 for Windows (SAS Institute Inc.,
Cary, NC). Since this was a hypothesis-generating ana-




A total of 163 participants were recruited into the study
of whom 110 (67%) had the necessary data to contribute
to testing the “primary” model. The single most
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common reason for exclusion from the analysis was the
absence of a baseline weight in 26% of the sample. The
demographic and clinical characteristics of those con-
tributing to this analysis are reported in Table 1. Across
all the demographic and clinical variables listed in
Table 1 through 3, only weight z score (but not BMI z
score) was different between those included and
excluded from the analysis.
The mean age at enrollment of the participants was
11.8 years (sd = 2.9) and the mean duration of treatment
with risperidone was 2.5 years (sd = 1.7). The majority
(81%, n = 89) received risperidone to target irritability
and aggression, after having failed to respond to other
psychotropics over 2.3 years (sd = 2.3).
As shown in Table 1, attention deficit hyperactivity
disorder (ADHD) and disruptive behavior disorders were
most common. As is typical for such a clinical sample,
comorbidity was prevalent, with a median number of
diagnoses of 2 (Interquartile range [IQR] = 1). Moreover,
polypharmacy was the rule with only 4% (n = 4) of the
sample taking risperidone alone. In fact, the median
number of psychotropics, taken in addition to risperi-
done, was 3 (IQR= 1), with psychostimulants, selective
serotonin reuptake inhibitors (SSRIs), and α2-agonists
(i.e., clonidine or guanfacine) being the most co-prescribed
(Table 2). Other psychotropics received upon enrollment
by a minority of participants include trazodone (n= 5),
imipramine (n= 4), clomipramine (n= 3), valproate
(n= 2), bupropion (n= 2), gabapentin (n= 2), lithium
(n= 1), oxcarbazepine (n= 1), topiramate (n= 1), lamotri-
gine (n= 1), levetiracetam (n= 1), buspirone (n= 1), and
venlafaxine (n= 1).
As previously reported [11], weight and BMI z scores
significantly increased, after risperidone was started, by
nearly 0.5 z score point (p< .0001) (Table 1).
Weight gain during risperidone treatment; “primary”
model
Over a period extending between 15.6 years before and
8.4 years after risperidone was started, a mean of 15.1
(sd = 12.2) weight measurements were available per
month for the sample. More than twice as many mea-
surements (mean = 31.7, sd = 10.9) per month were avail-
able for the period extending between 2.5 years before
and 2.5 years after risperidone was started.
Using mixed regression analysis to test the “primary”
model, baseline weight z score (β= 1.13, p< .0001), time
on risperidone (β= 0.16, p< .0001), and the weight-
adjusted dose of risperidone (β= 2.6, p< .0001) were all
Table 2 Clinical Characteristics of the Sample
Characteristic
Psychiatric Diagnoses, n (%)
Attention Deficit Hyperactivity Disorder 96 (87)
Disruptive Behavior Disorder 100 (91)
Anxiety Disorder 36 (33)
Tic Disorder 24 (22)
Depressive Disorder 12 (11)
Pervasive Developmental Disorder 14 (13)
Psychotic Disorder 1 (1)
Pharmacotherapy
Risperidone Dose, mg/d 1.4 (±1.1)
Risperidone Dose, mg/kg/d 0.03 (±0.02)
Age at Start of Risperidone, yrs 9.1 (±2.8)
Treatment Duration, yrs 2.5 (±1.7)
Psychostimulants, n (%) 78 (71)
Psychostimulants Dose, mg/d a 59.2 (±28.6)
Psychostimulants Dose, mg/kg/d a 1.35 (±0.70)
Psychostimulants Treatment Duration, yrs 4.8 (±2.7)




SSRI Dose, unit per day b 1.30 (±0.83)
SSRI Treatment Duration, yrs 2.6 (±2.1)
α2-agonists, n (%) 35 (32)
a All dosages of psychostimulants were expressed in methylphenidate
equivalents for amphetamines (x 2) [33].
b One SSRI unit is equivalent to a daily dose of 10 mg of escitalopram, 20 mg
of fluoxetine, citalopram, or paroxetine, and 50 mg of sertraline or
fluvoxamine [25].
Table 1 Demographic and Anthropometric Characteristics
of the Sample
Characteristic
Age, years 11.8 (±2.9)
Males, n (%) 98 (89%)
Tanner Stage: I, II, III, IV, V (%) 36/14/18/22/10
Race, n (%)
White 87 (79)




Birth Weight z Scorea (n=98) -0.29 (±0.99)
Baseline Weight z Scoreb 0.17 (±1.02)
Baseline BMI z Scoreb (n=107) 0.18 (±1.05)
Enrollment Weight, Kg 49.1 (±18.3)
Enrollment Weight z Score 0.72 (±1.03)
Enrollment Weight, Kg/m2 20.9 (±4.6)
Enrollment BMI z Score 0.73 (±1.02)
a This was adjusted for sex and gestational age [31].
b Baseline sex- and age-adjusted weight or body mass index (BMI) z scores
included those available upon or within the month prior to starting
risperidone.
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positively associated with weight z score. In addition, the
interaction effect of time and baseline weight z score
was significant (β=−0.05, p< .005) as well as that of
time and the weight-adjusted dose of psychostimulants
(β=−0.04, p< .0001). This suggests that, over time, the
association between baseline weight z score and subse-
quent measurements attenuates while that of psychosti-
mulants becomes more prominent. There was no
significant effect of age when risperidone was started
(p> .5).
Similarly, baseline BMI z score (β= 1.05, p< .0001),
time on risperidone (β= 0.16, p< .0001), and the weight-
adjusted dose of risperidone (β= 14.0, p< .0001) were
positively associated with BMI z score with the weight-
adjusted dose of psychostimulants being negatively so
(β=−0.19, p< .0001). Again, the effect of baseline BMI z
score wanes over time (interaction effect β=−0.05, p
< .02). In addition, the interaction effect of time and the
dose of risperidone was significant (interaction effect
β=−1.96, p< .001), also suggesting that the association
between the dose of risperidone and BMI z score
declines over the course of treatment.
Effect of concomitant psychotropics
Besides psychostimulants, SSRIs and α2-agonists were
the most commonly co-prescribed psychotropics in this
sample (Table 2). Thus, we investigated their potential
effect on risperidone-induced weight gain. The number
of SSRI units was negatively associated with weight z
score (β=−0.05, p = .0005) while both SSRIs and α2-
agonists were negatively associated with BMI z score
(β=−0.06, p< .04 and β=−0.14, p = .0006, respectively),
after accounting for the other “primary” covariates.
Effect of birth weight and growth rate in infancy
Birth weight z score, adjusted for gender and gestational
age, was significantly correlated with weight z score at
the onset of psychotropic treatment (Spearman’s r = 0.29,
p = .0007) but not with BMI z score (Spearman’s r = 0.13,
p> .1). However, it did not significantly contribute to
the mixed regression model of either weight or BMI z
score (both p values> .1), after accounting for the other
“primary” covariates.
Between birth and 2 years of life, weight z score
increased by an average of 0.6 (sd = 1.3). Of the 70 parti-
cipants who had this information available, 14% (n = 10)
showed a reduction of their weight z score by more than
0.67 point, 50% showed no significant change, and 36%
(n = 25) showed an increase by more than 0.67 point (i.e.,
catch-up group). This postnatal change in weight z score
did not significantly influence weight or BMI z score
during risperidone treatment, after accounting for the
other “primary” covariates (all p values> .1).
Effect of pre-risperidone change in weight or BMI z scores
Next, we explored whether the change in weight during
the 18 months prior to risperidone initiation improved
model prediction of weight gain in risperidone-treated
children. As described above, we estimated the slope of
change in weight z score for each individual and stan-
dardized it before entering it in the mixed regression
model as an additional covariate. Data were available to
compute this slope in 96 participants, of whom 33 had a
negative slope (i.e., they lost weight during that period),
45 had a null slope, and 18 had a positive one. After
accounting for the “primary” covariates, the slope of
weight z score did not significantly contribute to the
model. Similar results were found for BMI z score.
Effect of acute post-risperidone change in weight or BMI
z scores
We, then, explored whether the change in weight during
the first three months after risperidone was started was
associated with further weight z score changes. Again,
we estimated the slope of change in weight z score for
each individual and standardized it before entering it in
the mixed regression model as an additional covariate.
Data were available to compute this slope in 40 partici-
pants for the weight and in 17 for the BMI z score ana-
lyses. After accounting for the “primary” covariates, the
slope of change in weight z score during the first
3 months of treatment did not significantly contribute to
the model. However, there was a suggestion of a positive
association between the change in BMI z score during
the first 3 months of risperidone treatment and further
increase in BMI z score (β= 0.10, p< .1), after taking
into account the other “primary” covariates.
Effect of dietary intake, physical activity, and parental
BMI
Table 3 lists the mean values of the different variables
related to dietary intake and physical activity. After con-
trolling for the other covariates in the “primary” model,
neither dietary intake, nor physical activity, maternal
BMI, or paternal BMI obtained at enrollment signifi-
cantly contributed to the change in weight or BMI z
scores.
Discussion
To our knowledge, this is the first pediatric study, span-
ning several years before and after the onset of risperi-
done treatment, to identify several independent
correlates of change in weight (BMI). The possible con-
founding effect of other AAPs was removed by restrict-
ing this analysis to a single agent, risperidone, which is
the most commonly-used and best investigated anti-
psychotic in youths [1,5-7]. In addition, this sample
included a heterogeneous clinical group, representative
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of the general population treated with AAPs. While
baseline weight (or BMI) z score and the daily dose of
risperidone were associated with a higher weight (or
BMI) z score during risperidone treatment, these effects
subsided over time. On the other hand, psychostimu-
lants, SSRIs, and α2-agonists were associated with lower
weight (BMI).
Dose-dependent weight gain with risperidone
Studies in adults suggest that for some, but perhaps not
all, AAPs, weight gain and cardiometabolic abnormalities
are dose-dependent [34]. In children and adolescents,
short-term, randomized clinical trials and observational
studies have found weight gain to be dose-dependent for
risperidone and aripiprazole but not quetiapine [6,12,35].
The findings with risperidone are inconsistent, however,
perhaps because, in the one clinical trial in bipolar dis-
order that failed to find a dose effect, the treatment groups
were not matched on baseline weight [36]. Regardless, be-
cause of the short-term duration of these trials, it is diffi-
cult to make predictions about weight changes over longer
periods of exposure. Moreover, most pediatric clinical
trials conducted to date have not enrolled participants
based on weight at the onset of treatment or AAP-naïve
status, two related characteristics associated with AAP-
induced weight gain [11,12,22,37,38].
Another critical factor influencing a potential link be-
tween AAP dose and weight gain is medication adher-
ence. Adherence is often suboptimal during extended
treatment of any kind, but perhaps particularly so in the
population of children receiving AAPs. Furthermore,
treatment adherence is often challenging to capture ac-
curately in naturalistic long-term studies such as the one
reported here. This is particularly important since sev-
eral antipsychotic-related adverse events that could
potentially reduce adherence, such as sedation or hyper-
prolactinemia, are dose-dependent [36,39,40]. Finally,
adjusting the dose for weight, as we have done, or meas-
uring the medication serum concentration could in-
crease the sensitivity of dose as a predictor of weight
gain.
The factors mentioned above might explain some of
the inconsistency in the literature regarding the dose ef-
fect of AAPs on weight gain. Moreover, we found that
the dose of risperidone is associated with an increase in
BMI z score but this effect wanes over time. This too
could explain why only some studies have found a dose
effect. Since weight gain eventually plateaus, following
an interval whose duration is related to several factors
including baseline weight and status of prior treatment
with AAPs, it is likely that dose exerts a significant effect
during the initial phase of treatment but this gradually
wanes as weight gain nears its plateau. In other words,
our findings suggest that youth receiving a lower dose of
risperidone will gain weight at a slower rate. However,
during extended treatment, the eventual weight accrued
might be similar to when higher doses are used, since
each individual will eventually reach his/her new homeo-
static set point, as modified by AAP treatment. The
metabolic consequences of these differing trajectories
have been reported elsewhere [41].
Contribution of concurrent psychotropic medications
Psychostimulants are known to suppress appetite and
growth [32]; thus, investigators have explored whether
these medications protect against AAP-related weight
gain. Two large, short-term, studies failed to find a “pro-
tective” effect of concurrent psychostimulant treatment
[12,42]. A third, albeit smaller, study showed a similar
lack of effect [43]. However, such studies usually require
maintaining the dose of psychostimulants stable for a
period of time prior to and during AAP treatment. Un-
like in our prior publication where concomitant expos-
ure to psychostimulants was simply averaged across the
risperidone-treatment period [11], our current, more
precise, analysis revealed that a weight-adjusted dose of
concomitant psychostimulant therapy was associated
with less weight gain and that this effect seemed to per-
sist over time. Figure 1 illustrates the trajectory of BMI z
score of two, hypothetical, otherwise identical risperi-
done-treated children except that only one of them is re-
ceiving concurrent treatment with a psychostimulant.
In adults, acute SSRI monotherapy tends to either be
weight neutral or to reduce weight. However, an increase
in weight has been noted over longer periods of treat-
ment [44]. This effect varies across the different SSRIs,
with fluoxetine being least associated with weight gain
and paroxetine most [44]. While short-term studies have
described similar findings in children [45,46], to our




Total Calories, kcal/d 1926 (±772)
Protein Content, % 14.1 (±2.3)
Fat Content, % 32.1 (±4.4)
Carbohydrates Content, % 55.3 (±6.2)
Physical Activity
Sleep, hrs/day 8.6 (±3.1)
Screen Time, hrs/day a 2.9 (±2.1)
Days of Activity per Week 3.5 (±1.2)
Parent-rated Activity b 2.4 (±1.1)
a Screen time included the time spent watching television, playing video
games or on the computer, etc.
b Parent-rated activity was based on a single-item question asking the parent
to compare the child’s level of activity to his peers on a 5-point Likert scale
with 2 being equivalent to peers.
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knowledge, only one intermediate-term placebo con-
trolled pediatric trial of an SSRI reported weight
changes. In that multiphase study, fluoxetine led to a re-
duction in weight during the first 19 weeks [47]. This
appears to have partially recovered by week 51, though
the study suffered from a significant attrition [See
authors reply in ref [48]]. Fluoxetine was the most com-
monly used SSRI in our sample and no one received par-
oxetine (Table 2), perhaps explaining why SSRI
treatment was associated with less weight gain in our
sample. The limited number of participants receiving
various SSRIs, however, does not allow us to explore
their differential effect. Of note is that fluoxetine is a po-
tent inhibitor of the CYP2D6 enzyme which is the pre-
dominant pathway for risperidone metabolism. However,
the active moiety serum concentration (i.e., combined
risperidone and 9-hydroxyrisperidone concentration) is
at most minimally increased [49,50]. This could, theoret-
ically, accentuate weight gain from risperidone, although
the effect is likely negligible. One significant challenge is
how to validly capture effective SSRI exposure across
varying formulations, developmental stages, and levels of
medication adherence. We used the formula described
above because of the ease of its clinical use. However,
serotonin transporter occupancy might be more accurate
had this information been available for children as for
adults [51,52].
Alpha2-agonists can cause anorexia acutely but have
also been reported to cause weight gain [53]. To our
knowledge, the long-term effect of α2-agonists on
weight in youth has not been investigated in controlled
studies. Therefore, our finding of an inverse association
between the use of α2-agonists and BMI z score awaits
replication but highlights the complex potential out-
comes when multiple psychotropics are combined.
One note of caution is that the negative associations
between SSRIs and α2-agonists and weight do not
imply that these medications are “protective” against
risperidone-induced weight gain. Rather, they merely
suggest that risperidone-treated children who are con-
currently taking SSRIs or α2-agonists tend to have
lower weight/BMI. Therefore, our findings should be
interpreted cautiously and not considered to justify
polypharmacy.
Contribution of birth weight, caloric intake, physical
activity, and parental weight
Several studies have linked birth weight to weight later
in life [18]. Similarly, an association between rapid
growth in infancy or childhood and excessive weight and
insulin resistance later on has also been documented
[19]. These findings are believed to support the “thrifty
phenotype” hypothesis purporting that nutritionally-de-
priving conditions program the body to optimize energy
conservation [54]. When followed by free access to en-
ergy-rich food, this “homeostatic reprogramming” could
lead to excessive fat accumulation and the development
of obesity and insulin resistance [54]. We hypothesized
that the “thrifty phenotype” would accentuate the
increased energy intake or conservation associated with
risperidone treatment, thus leading to more weight gain.
However, neither birth weight nor postnatal growth
appeared to significantly contribute to risperidone-
related weight gain in our sample, after the other signifi-
cant factors were taken into account.
The contribution of high-calorie diets and a seden-
tary lifestyle to the obesity epidemic in the world is
well documented [20]. Moreover, interventions that
modify either one of these factors have resulted in
weight loss [20]. More specifically, AAPs induce
weight gain primarily by increasing appetite and cal-
oric intake [55-57], though they could reduce physical
activity due to sedation. We failed to find such an as-
sociation, perhaps because we collected these data
long after risperidone had been initiated and weight
gain stabilized. This might also explain why we did
not find an association between parental BMI and the
children’s propensity to gain weight.
Contribution of weight trajectories before and after
risperidone initiation
The discontinuation of psychostimulants is followed by





























Figure 1 Trajectory of weight gain with and without treatment
with psychostimulants. Estimated trajectory of BMI z score change
over a two-year period in a hypothetical participant on risperidone
monotherapy and one on a combination of risperidone and a
psychostimulant. These trajectories were modeled for a prototypical
participant using the sample mean for baseline BMI z score (0.13),
age at the onset of risperidone treatment (9.3 years), daily weight-
adjusted dose of risperidone (0.03 mg/kg/d) and methylphenidate
(0.9 mg/kg/d).
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prior treatment status is a strong correlate of AAP-
induced weight gain. Nonetheless, we found no signifi-
cant association between change in weight prior to the
onset of risperidone and the change afterwards.
Weight gain during the first few weeks of olanzapine
treatment is a strong predictor of future change in
weight [22,59]. We found only a statistical trend suggest-
ing that an increase in BMI z score during the first three
months of treatment is associated with further weight
gain during more extended treatment, after taking into
effect the other “primary” covariates. However, the sam-
ple size in this analysis was too small and requires future
replications.
The results reported here are subject to limitations.
First, it would be ideal if a randomized trial involving
various AAPs explored both efficacy and tolerability dur-
ing extended exposure. However, such a study is challen-
ging to conduct for ethical, budgetary, and practical
reasons. Alternatively, studies such as this one can help
fill the gap by providing sorely-needed information
about the long-term safety of AAPs using a more prag-
matic design. Nonetheless, this remains a retrospective
study with missing data, particularly regarding patients
who discontinue risperidone early on and, as a result,
are not enrolled. It is somewhat reassuring that the amp-
litude of weight gain we found is comparable to that
reported in shorter-term studies [12]. In addition, nearly
a third of our participants (53/163) were excluded from
the analysis due to missing data. They differed from the
included participants on enrollment weight, but not
BMI, z score. Thus, this finding could be due to a type I
error since it was the only variable that was significantly
different between the two groups across 39 tested. Sec-
ondly, the specific aim of the parent study was to inves-
tigate the metabolic and skeletal effects of risperidone
specifically in youths who have been receiving it over
extended periods of time. It is in these children that one
would be most concerned about long-term AAP safety,
making the results both relevant to common clinical
practice and generalizable to the broad population of
children treated with AAPs. Third, except for those
obtained upon study enrollment, all anthropometric
measurements were not necessarily collected following
standard procedures. However, like others [60], we
found weight and height measurements extracted from
the medical record to be highly correlated with the cor-
responding research measurements, obtained within a
month. Further, we contend that it is the trajectory of
change in weight (or BMI) during the course of treat-
ment, as opposed to single measurements, that is of
most clinical relevance. Modeling the weight (BMI) tra-
jectory requires serial measurements, making it less sus-
ceptible to measurement errors. Fourth, we used the
prescribed dose of risperidone as a predictor rather than
risperidone serum concentration. This is particularly im-
portant as the serum concentration, had it been obtained
repeatedly over the treatment course, would have better
captured medication adherence. As discussed earlier,
long-term adherence is challenging to estimate accur-
ately and tends to decrease over time. In fact, this
phenomenon could potentially explain the apparent at-
tenuation of the effect of risperidone dose on weight that
we found. Fifth, while comorbidity was common, the
prevalence of various disorders was somewhat bimodal
with ADHD and disruptive behavior disorders being al-
most universal with the other disorders afflicting a rela-
tive minority. This precluded our ability to explore
whether the underlying psychiatric disorders moderated
risperidone-related weight gain. Short-term randomized
pediatric trials in disruptive behavior, bipolar, psychotic,
tic, and pervasive developmental disorders have all
revealed a somewhat comparable weight gain with AAPs
[22,36,61-64]. However, none of these studies directly
compared weight gain across different disorders, leaving
unanswered the question of whether psychopathology
moderates one’s propensity to gain weight during AAP
treatment. Also, with the heritability of AAP-induced
weight gain estimated at 60 to 80% [65], it is likely that
genetic factors contribute to this adverse event as we
and others have shown [66,67]. These were not consid-
ered in the present analysis but should be in future ones.
Finally, it is important to replicate our findings in a lar-
ger sample where females and individuals from a diverse
racial/ethnic background are better represented.
Conclusions
In sum, we investigated the role of several demographic
and clinical factors in weight gain during extended ris-
peridone treatment in children. We found that baseline
weight and the dose of risperidone were associated with
weight gain but their effects subside as exposure con-
tinues. On the other hand, commonly co-prescribed
medications, including psychostimulants, SSRIs, and α2-
agonists, were associated with lower weight. Finally, add-
itional putative risk factors, like birth weight, postnatal
growth, physical activity, and dietary intake appear to
play a limited role, if any.
While no single intervention will be sufficient to ad-
dress a multi-factorial clinical problem like balancing the
risk/benefit ratio of AAP treatment, our findings shed
light on the complexity of how risperidone and com-
monly prescribed psychotropics influence weight gain
and obesity risk during long-term treatment in youths.
They specifically suggest that psychotropics play a po-
tentially important role in altering the trajectory of
weight gain during development. This effect might have
implications in the subsequent development of
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cardiometabolic abnormalities and, therefore, offers an
opportunity for preventive interventions.
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